Tumors, IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive
…, MH Shanik, D LeRoith, R Vigneri, CA Koch… - Endocrine …, 2013 - academic.oup.com
Tumors of mesenchymal and epithelial origin produce IGF-2, which activates pathways in
the tumors. In a minority of patients, the tumors (hepatomas, fibromas, and fibrosarcomas are …
the tumors. In a minority of patients, the tumors (hepatomas, fibromas, and fibrosarcomas are …
The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors
CA Koch, K Pacak, GP Chrousos - The Journal of Clinical …, 2002 - academic.oup.com
Modern imaging modalities lead to frequent detection of adrenal masses, most of them
incidental findings. Although the majority of adrenocortical and adrenomedullary tumors are …
incidental findings. Although the majority of adrenocortical and adrenomedullary tumors are …
Von Hippel-Lindau disease: current challenges and future prospects
S Gläsker, E Vergauwen, CA Koch… - OncoTargets and …, 2020 - Taylor & Francis
Understanding of molecular mechanisms of tumor growth has an increasing impact on the
development of diagnostics and targeted therapy of human neoplasia. In this review, we …
development of diagnostics and targeted therapy of human neoplasia. In this review, we …
SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins
CA Koch, D Anderson, MF Moran, C Ellis, T Pawson - Science, 1991 - science.org
Src homology (SH) regions 2 and 3 are noncatalytic domains that are conserved among a
series of cytoplasmic signaling proteins regulated by receptor protein-tyrosine kinases, …
series of cytoplasmic signaling proteins regulated by receptor protein-tyrosine kinases, …
CARE guidelines for case reports: explanation and elaboration document
…, D Moher, RA Rison, L Shamseer, CA Koch… - Journal of clinical …, 2017 - Elsevier
Background Well-written and transparent case reports (1) reveal early signals of potential
benefits, harms, and information on the use of resources; (2) provide information for clinical …
benefits, harms, and information on the use of resources; (2) provide information for clinical …
Binding of SH2 domains of phospholipase Cγ1, GAP, and Src to activated growth factor receptors
D Anderson, CA Koch, L Grey, C Ellis, MF Moran… - Science, 1990 - science.org
… we did not calibrate signals in terms of free Ca concentration. 14. DC Ogden, T. … (NCIC)
and the Medical Research Council of Canada (MRC). DA and MFM are postdoctoral fellows of …
and the Medical Research Council of Canada (MRC). DA and MFM are postdoctoral fellows of …
Src homology region 2 domains direct protein-protein interactions in signal transduction.
MF Moran, CA Koch, D Anderson… - Proceedings of the …, 1990 - National Acad Sciences
… is a Terry Fox Cancer Research Scientist of the National Cancer Institute of Canada. CAK
and LE hold student fellowships from the Medical Research Council of Canada and the …
and LE hold student fellowships from the Medical Research Council of Canada and the …
Chromosome micromanipulation: Iii. spindle fiber tension and the reorientation of mal-oriented chromosomes
RB Nicklas, CA Koch - The Journal of cell biology, 1969 - rupress.org
Kinetochore reorientation is the critical process ensuring normal chromosome distribution.
Reorientation has been studied in living grasshopper spermatocytes, in which bivalents with …
Reorientation has been studied in living grasshopper spermatocytes, in which bivalents with …
Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment
Objective To define associated clinical conditions, pathology, natural history, and treatment
outcome of nonhepatosplenic extramedullary hematopoiesis (NHS-EMH). Patients and …
outcome of nonhepatosplenic extramedullary hematopoiesis (NHS-EMH). Patients and …
Germline CDKN1B/p27Kip1 Mutation in Multiple Endocrine Neoplasia
…, R Paschke, O Gimm, CA Koch… - The Journal of …, 2007 - academic.oup.com
Context: Germline mutations in the MEN1 gene predispose to multiple endocrine neoplasia
type 1 (MEN1) syndrome, but in up to 20–25% of clinical MEN1 cases, no MEN1 mutations …
type 1 (MEN1) syndrome, but in up to 20–25% of clinical MEN1 cases, no MEN1 mutations …